During 2016, InMed achieved some significant milestones, including:
Induction of strong biopharmaceutical expertise in their senior management team
Financial closures to fund continued drug/disease target identification
Advanced analysis of existing datasets to ensure clinical development plans are accurate and positioned to maximize the likelihood for positive outcomes
Validation and advancement of the manufacturing process
Filing of provisional patents
Expanded scope of opportunities for cannabinoid-based products
The company continues to focus on research into fundamental benefits of cannabinoid drugs to address high unmet medical needs, selective advancement of high-potential drug candidates, identification and retention of industry veterans to define and execute the present & future drug development programs in a time- and cost-effective manner, collaboration with biotech-savvy investor groups & exploration into the partnership potential of the various programs and assets.
InMed Pharmaceuticals Inc. is a pre-clinical stage biopharmaceutical company specializing in the research, development and commercialization of cannabinoid-based therapies to treat human diseases with high unmet medical needs. The Company has three core assets: a proprietary Bioinformatics assessment tool to match individual (or combination of) cannabinoids against disease targets, a proprietary Biosynthesis cannabinoid manufacturing system to economically produce all 90+ cannabinoids at pharmaceutical-grade (>99.5% purity), and drug development program.
Read More